OraSure Technologies, Inc. (OSUR) Director Stephen S. Phd Tang Sells 23,333 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total transaction of $419,294.01. Following the sale, the director now owns 59,749 shares in the company, valued at $1,073,689.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

OraSure Technologies, Inc. (OSUR) opened at $17.86 on Wednesday. The company has a market cap of $1,080.00, a P/E ratio of 35.02, a price-to-earnings-growth ratio of 5.10 and a beta of 1.42. OraSure Technologies, Inc. has a one year low of $10.75 and a one year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The company had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm’s revenue was up 46.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.13 earnings per share. analysts expect that OraSure Technologies, Inc. will post 0.29 EPS for the current fiscal year.

A number of analysts recently weighed in on the stock. BidaskClub lowered shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 15th. Canaccord Genuity restated a “buy” rating and set a $24.00 target price on shares of OraSure Technologies in a research note on Friday, February 2nd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Friday, February 9th. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Jefferies Group lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. OraSure Technologies currently has a consensus rating of “Buy” and a consensus target price of $22.25.

Institutional investors have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. purchased a new position in OraSure Technologies in the third quarter valued at approximately $186,000. ARP Americas LLC purchased a new position in OraSure Technologies in the third quarter valued at approximately $221,000. Noesis Capital Mangement Corp purchased a new position in OraSure Technologies in the third quarter valued at approximately $225,000. Shikiar Asset Management Inc. purchased a new position in OraSure Technologies in the fourth quarter valued at approximately $207,000. Finally, Piedmont Investment Advisors LLC purchased a new position in OraSure Technologies in the second quarter valued at approximately $216,000. Institutional investors own 89.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “OraSure Technologies, Inc. (OSUR) Director Stephen S. Phd Tang Sells 23,333 Shares of Stock” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2018/02/21/orasure-technologies-inc-osur-director-stephen-s-phd-tang-sells-23333-shares-of-stock.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply